<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021056</url>
  </required_header>
  <id_info>
    <org_study_id>NFHCC-01</org_study_id>
    <nct_id>NCT04021056</nct_id>
  </id_info>
  <brief_title>Observational Study on Patients With Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Observational Study on Patients With Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical
      cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed
      and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed
      up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the overall survival rate of all HCC patients</measure>
    <time_frame>10 years</time_frame>
    <description>In order to identify the potential influence factors of HCC patients survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the recurrence free survival rate of HCC patients after curative treatments</measure>
    <time_frame>10 years</time_frame>
    <description>In order to identify the potential influence factors of tumor recurrence</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed and treated as HCC in Liver Cancer Center, Nanfang Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of HCC;

          -  Age ≥ 16 years;

          -  Received treatment targeting for HCC at least once, including operation, ablation,
             TACE, sorafenib, radiotherapy, chemotherapy, etc;

          -  Good compliance with clinical treatment.

        Exclusion Criteria:

          -  Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver
             cancer;

          -  Received only traditional Chinese medicine or symptomatic supportive treatment; (3)
             survival time ≤ 7 days;

          -  HCC diagnosed after liver transplantation;

          -  Poor compliance or important data deficient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinlin Hou</last_name>
    <email>jlhousmu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinlin Hou</last_name>
      <email>jlhousmu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Jinlin Hou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

